MEGAPORT-LIMITED
14.12.2021 23:02:07 CET | Business Wire | Press release
Megaport Limited (ASX: MP1) ("Megaport"), a global leading Network as a Service (NaaS) provider, today announces the availability of VMware SD-WAN on Megaport Virtual Edge (MVE). VMware SD-WAN’s will be interoperable with MVE to enable branch-to-cloud connectivity on Megaport’s global Software Defined Network (SDN).
Optimising VMware SD-WAN Connectivity
Many businesses have embraced SD-WAN and internet connections as a means of simplifying their IT connectivity. With VMware SD-WAN available on MVE, customers can host localised virtual SD-WAN controllers on Megaport’s global platform and reduce the distance data traverses over internet paths from branch locations to critical services in public or private clouds and even other branch locations.
Once connected, VMware customers can access Megaport’s leading ecosystem of more than 700 enabled data centres worldwide and over 360 service providers, including 220+ cloud on-ramps from the world's leading clouds such as Alibaba Cloud, AWS, Google Cloud, Microsoft Azure, IBM Cloud, Oracle Cloud, and Salesforce.
VMware SD-WAN on MVE Highlights:
- Reduced cloud egress costs to cloud on-ramps when compared to internet rates.
- Globally distributed for localised connections.
- Point-and-click network provisioning to support interconnection between branch locations, data centres, cloud providers, and IT services.
- Real-time provisioning of virtual network infrastructure and interconnections.
- No hardware to ship, install, or manage.
- Unified end-to-end network provisioning and management to transform legacy networks.
- More secure, multi-cloud connections to more than 360 service providers, 700+ enabled data centres, and 220+ cloud interconnect points.
Craig Connors, vice president and general manager at VMware, said, “VMware SD-WAN in combination with Megaport Virtual Edge offers customers more choice for simplifying WAN operations, reliable network performance for business-critical applications, and easier adoption of hybrid cloud and multi-cloud, while reducing latency to cloud workloads.”
Transforming Networking at the Edge
MVE is a globally distributed compute and network service in one. The compute aspect of the service enables customers to host NFV instances in locations where they need them, on demand, and manage them in a point-and-click manner. On the network side, MVE’s built-in transit gateway provides a highly scalable access point for connecting networks, via the public internet, to Megaport’s private SDN. Virtualised devices hosted on MVE can utilise the transit gateway to create connections between the Megaport SDN and their own networks, including branch locations, data centres, and private clouds.
MVE is available in 24 metros across North America, Asia-Pacific, and Europe. This allows customers more flexibility to deploy virtual devices near concentrations of users to localise traffic and optimise data termination for performance.
“As enterprises and service providers rapidly adopt SD-WAN technology to improve edge network connectivity, the ability for Megaport customers to easily, and in minutes, ‘spin up’ VMware SD-WAN edge routers around the world on our platform is a big enabler for global organisations,” said Vincent English, CEO of Megaport. “Having VMware SD-WAN in Megaport’s global Software Defined Network allows our customers to optimise their SD-WAN connectivity to improve overall network and application performance at a fraction of the cost of legacy methods.”
For more information about Megaport Virtual Edge, please visit https://www.megaport.com/mve .
For more information about VMware SD-WAN, learn more at https://sdwan.vmware.com/ .
VMware and VMware SD-WAN are registered trademarks or trademarks of VMware, Inc. or its subsidiaries in the United States and other jurisdictions.
About Megaport
Megaport is a leading provider of Network as a Service (NaaS) solutions. The company’s global Software Defined Network (SDN) helps businesses rapidly connect their network to services via an easy-to-use portal or our open API. Megaport offers agile networking capabilities that reduce operating costs and increase speed to market compared to traditional networking solutions. Megaport partners with the world’s top cloud service providers, including AWS, Microsoft Azure, and Google Cloud, as well as the largest data centre operators, systems integrators and managed service providers in the world. Megaport is an ISO/IEC 27001-certified company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005135/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom